Differences in clinical features between CA-125 and RECIST progression in patients with ovarian cancer treated with PARP inhibitors. Efficacy and safety of envafolimab plus lenvatinib combined with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback